{"id":2307,"date":"2016-05-18T00:00:00","date_gmt":"2016-05-18T00:00:00","guid":{"rendered":"https:\/\/blog.caixaresearch.org\/?p=2307"},"modified":"2020-05-05T08:33:37","modified_gmt":"2020-05-05T08:33:37","slug":"la-resistencia-terapeutica-es-el-principal-problema-en-la-curacio-del-cancer","status":"publish","type":"post","link":"https:\/\/blog.caixaresearch.org\/ca\/la-resistencia-terapeutica-es-el-principal-problema-en-la-curacio-del-cancer\/","title":{"rendered":"La resist\u00e8ncia terap\u00e8utica \u00e9s el principal problema en la curaci\u00f3 del c\u00e0ncer"},"content":{"rendered":"<p><html><body><\/p>\n<div class=\"post_content\">\n<p><style type=\"text\/css\">em{font-style:italic!important}<\/style>\n<\/p>\n<div style=\"text-align: justify;\"> <img decoding=\"async\" alt=\"\" src=\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2020\/04\/ca\/los-colideres-de-este-b-debate-son-joaquin-arribas-profesor-de-investigacion-icrea-y-director-de-investigacion-preclinica-de.jpg\" style=\"width: 400px; height: 267px;\"\/><\/div>\n<p style=\"text-align: justify;\"> <span style=\"line-height: 1.4;\"><em>Post de <strong>Miquel \u00c0ngel Pujana<\/strong>, director del nou programa ProCURE contra la resist\u00e8ncia terap\u00e8utica del c\u00e0ncer de l&#8217;Institut Catal\u00e0 d&#8217;Oncologia (ICO). Col\u00edder cient\u00edfic del <a href=\"http:\/\/www.bdebate.org\/debat\/cancer-therapeutic-resistance-progress-and-perspectives\" rel=\"noopener noreferrer\" target=\"_blank\">B-Debate sobre la \u00abResist\u00e8ncia terap\u00e8utica del c\u00e0ncer: progressos i perspectives\u00bb<\/a>.<\/em><\/span><\/p>\n<p style=\"text-align: justify;\"> La resist\u00e8ncia d&#8217;alguns tipus de c\u00e0ncer a les ter\u00e0pies \u00e9s el principal obstacle en la curaci\u00f3 de la malaltia. A Catalunya, cada any es diagnostiquen uns 34.000 casos nous de c\u00e0ncer, dels quals el 30% desenvolupen resist\u00e8ncia terap\u00e8utica als f\u00e0rmacs.<\/p>\n<p style=\"text-align: justify;\"> Diversos experts internacionals ens vam reunir a CosmoCaixa a principis d&#8217;abril de 2016 per discutir en un <a href=\"http:\/\/www.bdebate.org\" rel=\"noopener noreferrer\" target=\"_blank\">B-Debate<\/a>, iniciativa de <a href=\"http:\/\/www.biocat.cat\/ca\" rel=\"noopener noreferrer\" target=\"_blank\">Biocat<\/a> i l&#8217;<a href=\"https:\/\/obrasociallacaixa.org\/ca\/\" rel=\"noopener noreferrer\" target=\"_blank\">Obra Social &#8220;la Caixa&#8221;<\/a>, sobre les millors estrat\u00e8gies per combatre la resist\u00e8ncia del c\u00e0ncer a les ter\u00e0pies.<\/p>\n<p style=\"text-align: justify;\"> <strong>Principal obstacle en la curaci\u00f3 del c\u00e0ncer<\/strong><\/p>\n<p style=\"text-align: justify;\"> La resist\u00e8ncia terap\u00e8utica \u00e9s el principal obstacle per a la curaci\u00f3 del c\u00e0ncer. En els darrers anys la medicina personalitzada o de precisi\u00f3 s&#8217;ha consolidat com l&#8217;estrat\u00e8gia terap\u00e8utica predominant per combatre el c\u00e0ncer: en el per\u00edode 2010-2014 es van aprovar 45 nous f\u00e0rmacs adre\u00e7ats contra lesions moleculars concretes. Aquest tipus de tractament, acompanyat de cirurgia, \u00e9s capa\u00e7 de reduir i controlar el tumor d&#8217;alguns pacients, per\u00f2 hi ha casos en qu\u00e8 el tumor reapareix i la malaltia no respon a l\u00ednies de tractament posteriors. En aquests casos, les c\u00e8l\u00b7lules tumorals s&#8217;adapten i recreixen tot i la medicaci\u00f3.<\/p>\n<p style=\"text-align: justify;\"> <strong>La superviv\u00e8ncia ha augmentat<\/strong><\/p>\n<p style=\"text-align: justify;\"> La resist\u00e8ncia d&#8217;alguns c\u00e0ncers a les ter\u00e0pies afecta en gran mesura la superviv\u00e8ncia dels pacients. El 1990 nom\u00e9s la meitat dels diagnosticats amb c\u00e0ncer seguia viu al cap de cinc anys; ara en sobreviu el 67%. El cas paradigm\u00e0tic \u00e9s el del melanoma: fa uns anys la meitat dels pacients amb un c\u00e0ncer de pell amb met\u00e0stasi no sobrevivia m\u00e9s de sis o set mesos, i ara m\u00e9s de la meitat superen els dos anys de vida. L&#8217;escenari del c\u00e0ncer de pulm\u00f3 \u00e9s similar. En altres tumors, per\u00f2, s&#8217;ha avan\u00e7at menys. Per exemple, el c\u00e0ncer d&#8217;ovari es tracta de la mateixa manera que durant les tres \u00faltimes d\u00e8cades i, per la seva biologia, l&#8217;aparici\u00f3 de resist\u00e8ncia representa un problema cl\u00ednic freq\u00fcent. En general, podem afirmar que entre el 10% i el 70% dels pacients oncol\u00f2gics patiran aquest problema (depenent de les caracter\u00edstiques tumorals, el moment del diagn\u00f2stic o el tipus de ter\u00e0pia aplicada, entre altres factors).<\/p>\n<div style=\"text-align: justify;\"> <img decoding=\"async\" alt=\"\" src=\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2020\/04\/ca\/el-7-y-8-de-abril-se-reunen-en-cosmocaixa-expertos-internacionales-convocados-por-b-debate-centro-internacional-para-el-deba.jpg\" style=\"width: 400px; height: 267px;\"\/><\/div>\n<div style=\"text-align: justify;\"> <span style=\"font-size: 11px; line-height: 1.4;\">Presentaci\u00f3 del B-Debate sobre la resist\u00e8ncia terap\u00e8utica del c\u00e0ncer, que ha comptat com a l\u00edders cient\u00edfics amb Miquel \u00c0ngel Pujana, director del nou programa ProCURE contra la resist\u00e8ncia terap\u00e8utica del c\u00e0ncer de l&#8217;Institut Catal\u00e0 d&#8217;Oncologia (ICO), i Joaquin Arribas, professor d&#8217;investigaci\u00f3 ICREA i director d&#8217;investigaci\u00f3 precl\u00ednica del Vall d&#8217;Hebron Institut d&#8217;Oncologia (VHIO). Imatge: Obra Social &#8220;la Caixa&#8221;.<\/span><\/div>\n<p style=\"text-align: justify;\"> Un altre dels temes centrals en el camp de la resist\u00e8ncia a les ter\u00e0pies, a part de la superviv\u00e8ncia dels pacients, \u00e9s la despesa farmac\u00e8utica. A Fran\u00e7a, Alemanya, It\u00e0lia, Espanya i el Regne Unit prop del 15% del pressupost en salut l&#8217;any 2014 es va destinar a medicaments oncol\u00f2gics. La despesa econ\u00f2mica en f\u00e0rmacs s&#8217;ha incrementat pel fet que n&#8217;ha augmentat el diagn\u00f2stic preco\u00e7 i que les ter\u00e0pies duren m\u00e9s temps. En aquest context, segons els c\u00e0lculs de l&#8217;ICO, que proporciona assist\u00e8ncia oncol\u00f2gica al 50% de la poblaci\u00f3 adulta a Catalunya, depenent del tipus tumoral, entre el 40% i el 70% de la despesa farmac\u00e8utica es dedica a combatre <em>resist\u00e8ncies.<\/em><\/p>\n<p style=\"text-align: justify;\"> <strong>Progressos en els tractaments oncol\u00f2gics<\/strong><\/p>\n<p style=\"text-align: justify;\"> La immunoter\u00e0pia oncol\u00f2gica, escollida per la revista <em>Science<\/em> com l&#8217;aven\u00e7 m\u00e9s important del 2013, \u00e9s l&#8217;esperan\u00e7a dels nous tractaments oncol\u00f2gics: estimula el sistema immunitari propi perqu\u00e8 lluiti contra les c\u00e8l\u00b7lules cancer\u00edgenes. El primer f\u00e0rmac que aplica aquest tipus de ter\u00e0pia es va aprovar per combatre el melanoma. Aquest tractament permetia que, per primera vegada, les pr\u00f2pies defenses del malalt reconeguessin les c\u00e8l\u00b7lules tumorals i, per tant, poguessin lluitar-hi en contra, amb la conseg\u00fcent millora de la superviv\u00e8ncia dels pacients.<\/p>\n<p style=\"text-align: justify;\"> <strong>M\u00e9s informaci\u00f3<\/strong><\/p>\n<p style=\"text-align: justify;\"> <a href=\"http:\/\/www.bdebate.org\/debat\/cancer-therapeutic-resistance-progress-and-perspectives\" rel=\"noopener noreferrer\" target=\"_blank\">B-Debate \u00abCancer Therapeutic Resistance. Progress and Perspectives\u00bb<\/a><\/p>\n<p style=\"text-align: justify;\"> <a href=\"http:\/\/www.biocat.cat\/en\/reportages\/synopsis-bdebate-treating-cancer-fight-against-resistance\" rel=\"noopener noreferrer\" target=\"_blank\">Report: Synopsis B\u00b7Debate &#8211; Treating cancer: the fight against resistance<\/a><\/p>\n<\/p><\/div>\n<p><\/body><\/html><\/p>\n","protected":false},"excerpt":{"rendered":"<\/p>\n<p><style type=\"text\/css\">em{font-style:italic!important}<\/style>\n<\/p>\n<p> <img decoding=\"async\" alt=\"\" src=\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2020\/04\/ca\/los-colideres-de-este-b-debate-son-joaquin-arribas-profesor-de-investigacion-icrea-y-director-de-investigacion-preclinica-de.jpg\" style=\"width: 400px; height: 267px;\"\/><\/p>\n<p style=\"text-align: justify;\"> <em>Post de Miquel \u00c0ngel Pujana, director del nou programa ProCURE contra la resist\u00e8ncia terap\u00e8utica del c\u00e0ncer de l&#8217;Institut Catal\u00e0 d&#8217;Oncologia (ICO). Col\u00edder cient\u00edfic del <a href=\"http:\/\/www.bdebate.org\/debat\/cancer-therapeutic-resistance-progress-and-perspectives\" rel=\"noopener noreferrer\" target=\"_blank\">B-Debate sobre la \u00abResist\u00e8ncia terap\u00e8utica del c\u00e0ncer: progressos i perspectives\u00bb<\/a>.<\/em><\/p>\n<p style=\"text-align: justify;\"> La resist\u00e8ncia d&#8217;alguns tipus de c\u00e0ncer a les ter\u00e0pies \u00e9s el principal obstacle en la curaci\u00f3 de la malaltia. A Catalunya, cada any es diagnostiquen uns 34.000 casos nous de c\u00e0ncer, dels quals el 30% desenvolupen resist\u00e8ncia terap\u00e8utica als f\u00e0rmacs.<\/p>\n<p style=\"text-align: justify;\"> Diversos experts internacionals ens vam reunir a CosmoCaixa a principis d&#8217;abril de 2016 per discutir en un <a href=\"http:\/\/www.bdebate.org\" rel=\"noopener noreferrer\" target=\"_blank\">B-Debate<\/a>, iniciativa de <a href=\"http:\/\/www.biocat.cat\/ca\" rel=\"noopener noreferrer\" target=\"_blank\">Biocat<\/a> i l&#8217;<\/p>\n","protected":false},"author":1,"featured_media":2900,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[519],"tags":[256,36],"class_list":["post-2307","post","type-post","status-publish","format-standard","hentry","category-investigacio","tag-bdebate","tag-cancer"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>La resist\u00e8ncia terap\u00e8utica \u00e9s el principal problema en la curaci\u00f3 del c\u00e0ncer - Blog CaixaCi\u00e8ncia<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blog.caixaresearch.org\/ca\/la-resistencia-terapeutica-es-el-principal-problema-en-la-curacio-del-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La resist\u00e8ncia terap\u00e8utica \u00e9s el principal problema en la curaci\u00f3 del c\u00e0ncer - Blog CaixaCi\u00e8ncia\" \/>\n<meta property=\"og:description\" content=\"Post de Miquel \u00c0ngel Pujana, director del nou programa ProCURE contra la resist\u00e8ncia terap\u00e8utica del c\u00e0ncer de l&#8217;Institut Catal\u00e0 d&#8217;Oncologia (ICO). Col\u00edder cient\u00edfic del B-Debate sobre la \u00abResist\u00e8ncia terap\u00e8utica del c\u00e0ncer: progressos i perspectives\u00bb. La resist\u00e8ncia d&#8217;alguns tipus de c\u00e0ncer a les ter\u00e0pies \u00e9s el principal obstacle en la curaci\u00f3 de la malaltia. A Catalunya, cada any es diagnostiquen uns 34.000 casos nous de c\u00e0ncer, dels quals el 30% desenvolupen resist\u00e8ncia terap\u00e8utica als f\u00e0rmacs. Diversos experts internacionals ens vam reunir a CosmoCaixa a principis d&#8217;abril de 2016 per discutir en un B-Debate, iniciativa de Biocat i l&#8217;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blog.caixaresearch.org\/ca\/la-resistencia-terapeutica-es-el-principal-problema-en-la-curacio-del-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog CaixaCi\u00e8ncia\" \/>\n<meta property=\"article:published_time\" content=\"2016-05-18T00:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-05-05T08:33:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2020\/04\/ca\/los-colideres-de-este-b-debate-son-joaquin-arribas-profesor-de-investigacion-icrea-y-director-de-investigacion-preclinica-de.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"267\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"La Caixa\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"La Caixa\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blog.caixaresearch.org\/ca\/la-resistencia-terapeutica-es-el-principal-problema-en-la-curacio-del-cancer\/\",\"url\":\"https:\/\/blog.caixaresearch.org\/ca\/la-resistencia-terapeutica-es-el-principal-problema-en-la-curacio-del-cancer\/\",\"name\":\"La resist\u00e8ncia terap\u00e8utica \u00e9s el principal problema en la curaci\u00f3 del c\u00e0ncer - Blog CaixaCi\u00e8ncia\",\"isPartOf\":{\"@id\":\"https:\/\/blog.caixaresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/blog.caixaresearch.org\/ca\/la-resistencia-terapeutica-es-el-principal-problema-en-la-curacio-del-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/blog.caixaresearch.org\/ca\/la-resistencia-terapeutica-es-el-principal-problema-en-la-curacio-del-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2020\/04\/ca\/los-colideres-de-este-b-debate-son-joaquin-arribas-profesor-de-investigacion-icrea-y-director-de-investigacion-preclinica-de.jpg\",\"datePublished\":\"2016-05-18T00:00:00+00:00\",\"dateModified\":\"2020-05-05T08:33:37+00:00\",\"author\":{\"@id\":\"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/c4ed33a98e6581c876664e7035da245a\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blog.caixaresearch.org\/ca\/la-resistencia-terapeutica-es-el-principal-problema-en-la-curacio-del-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/blog.caixaresearch.org\/ca\/la-resistencia-terapeutica-es-el-principal-problema-en-la-curacio-del-cancer\/#primaryimage\",\"url\":\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2020\/04\/ca\/los-colideres-de-este-b-debate-son-joaquin-arribas-profesor-de-investigacion-icrea-y-director-de-investigacion-preclinica-de.jpg\",\"contentUrl\":\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2020\/04\/ca\/los-colideres-de-este-b-debate-son-joaquin-arribas-profesor-de-investigacion-icrea-y-director-de-investigacion-preclinica-de.jpg\",\"width\":400,\"height\":267},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blog.caixaresearch.org\/#website\",\"url\":\"https:\/\/blog.caixaresearch.org\/\",\"name\":\"Blog CaixaCi\u00e8ncia\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blog.caixaresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/c4ed33a98e6581c876664e7035da245a\",\"name\":\"La Caixa\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d49b93050814699a8c78e1e6223735d5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d49b93050814699a8c78e1e6223735d5?s=96&d=mm&r=g\",\"caption\":\"La Caixa\"},\"sameAs\":[\"https:\/\/blog.caixaresearch.org\"],\"url\":\"https:\/\/blog.caixaresearch.org\/ca\/author\/caixaciencialamagnetica-net\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La resist\u00e8ncia terap\u00e8utica \u00e9s el principal problema en la curaci\u00f3 del c\u00e0ncer - Blog CaixaCi\u00e8ncia","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blog.caixaresearch.org\/ca\/la-resistencia-terapeutica-es-el-principal-problema-en-la-curacio-del-cancer\/","og_locale":"ca_ES","og_type":"article","og_title":"La resist\u00e8ncia terap\u00e8utica \u00e9s el principal problema en la curaci\u00f3 del c\u00e0ncer - Blog CaixaCi\u00e8ncia","og_description":"Post de Miquel \u00c0ngel Pujana, director del nou programa ProCURE contra la resist\u00e8ncia terap\u00e8utica del c\u00e0ncer de l&#8217;Institut Catal\u00e0 d&#8217;Oncologia (ICO). Col\u00edder cient\u00edfic del B-Debate sobre la \u00abResist\u00e8ncia terap\u00e8utica del c\u00e0ncer: progressos i perspectives\u00bb. La resist\u00e8ncia d&#8217;alguns tipus de c\u00e0ncer a les ter\u00e0pies \u00e9s el principal obstacle en la curaci\u00f3 de la malaltia. A Catalunya, cada any es diagnostiquen uns 34.000 casos nous de c\u00e0ncer, dels quals el 30% desenvolupen resist\u00e8ncia terap\u00e8utica als f\u00e0rmacs. Diversos experts internacionals ens vam reunir a CosmoCaixa a principis d&#8217;abril de 2016 per discutir en un B-Debate, iniciativa de Biocat i l&#8217;","og_url":"https:\/\/blog.caixaresearch.org\/ca\/la-resistencia-terapeutica-es-el-principal-problema-en-la-curacio-del-cancer\/","og_site_name":"Blog CaixaCi\u00e8ncia","article_published_time":"2016-05-18T00:00:00+00:00","article_modified_time":"2020-05-05T08:33:37+00:00","og_image":[{"width":400,"height":267,"url":"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2020\/04\/ca\/los-colideres-de-este-b-debate-son-joaquin-arribas-profesor-de-investigacion-icrea-y-director-de-investigacion-preclinica-de.jpg","type":"image\/jpeg"}],"author":"La Caixa","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"La Caixa","Temps estimat de lectura":"4 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/blog.caixaresearch.org\/ca\/la-resistencia-terapeutica-es-el-principal-problema-en-la-curacio-del-cancer\/","url":"https:\/\/blog.caixaresearch.org\/ca\/la-resistencia-terapeutica-es-el-principal-problema-en-la-curacio-del-cancer\/","name":"La resist\u00e8ncia terap\u00e8utica \u00e9s el principal problema en la curaci\u00f3 del c\u00e0ncer - Blog CaixaCi\u00e8ncia","isPartOf":{"@id":"https:\/\/blog.caixaresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blog.caixaresearch.org\/ca\/la-resistencia-terapeutica-es-el-principal-problema-en-la-curacio-del-cancer\/#primaryimage"},"image":{"@id":"https:\/\/blog.caixaresearch.org\/ca\/la-resistencia-terapeutica-es-el-principal-problema-en-la-curacio-del-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2020\/04\/ca\/los-colideres-de-este-b-debate-son-joaquin-arribas-profesor-de-investigacion-icrea-y-director-de-investigacion-preclinica-de.jpg","datePublished":"2016-05-18T00:00:00+00:00","dateModified":"2020-05-05T08:33:37+00:00","author":{"@id":"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/c4ed33a98e6581c876664e7035da245a"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blog.caixaresearch.org\/ca\/la-resistencia-terapeutica-es-el-principal-problema-en-la-curacio-del-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/blog.caixaresearch.org\/ca\/la-resistencia-terapeutica-es-el-principal-problema-en-la-curacio-del-cancer\/#primaryimage","url":"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2020\/04\/ca\/los-colideres-de-este-b-debate-son-joaquin-arribas-profesor-de-investigacion-icrea-y-director-de-investigacion-preclinica-de.jpg","contentUrl":"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2020\/04\/ca\/los-colideres-de-este-b-debate-son-joaquin-arribas-profesor-de-investigacion-icrea-y-director-de-investigacion-preclinica-de.jpg","width":400,"height":267},{"@type":"WebSite","@id":"https:\/\/blog.caixaresearch.org\/#website","url":"https:\/\/blog.caixaresearch.org\/","name":"Blog CaixaCi\u00e8ncia","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blog.caixaresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Person","@id":"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/c4ed33a98e6581c876664e7035da245a","name":"La Caixa","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d49b93050814699a8c78e1e6223735d5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d49b93050814699a8c78e1e6223735d5?s=96&d=mm&r=g","caption":"La Caixa"},"sameAs":["https:\/\/blog.caixaresearch.org"],"url":"https:\/\/blog.caixaresearch.org\/ca\/author\/caixaciencialamagnetica-net\/"}]}},"_links":{"self":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts\/2307","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/comments?post=2307"}],"version-history":[{"count":2,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts\/2307\/revisions"}],"predecessor-version":[{"id":3556,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts\/2307\/revisions\/3556"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/media\/2900"}],"wp:attachment":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/media?parent=2307"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/categories?post=2307"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/tags?post=2307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}